Because K63-linkage specific poly-ubiquitination of AKT is prerequisite for its activation and MEK inhibitors have been shown to activate AKT in various breast cancer cell lines [43], we evaluated the sensitivity of K63UbR using a MEK inhibitor (CI-1040). This evidence concerns the gene MAP2K7 and breast carcinoma.